For decades, pancreatic cancer has been almost impossible to treat. A new drug targeting the mutation driving 90% of cases may finally be changing that — and patients won’t have to wait long to access it.

Scientists have spent decades trying to drug the KRAS mutation — often called “undruggable.” A new compound called daraxonrasib may have finally cracked it. (Photo placeholder — replace with licensed image)

Survival improvement ~2x vs. prior standard of care

Reduction in death risk 60% Phase 3 trial results

Pancreatic cancers with KRAS mutation 90%+ the target this drug hits

Expected FDA approval 2026 late this year or early 2027

If you’ve ever known someone with pancreatic cancer — and statistically, many of us have — you know the conversation that follows a diagnosis tends to move very quickly from “treatment options” to “getting your affairs in order.” The five-year survival rate has hovered around 12% for years. It is, bluntly, one of the cancers doctors dread telling patients they have.

That’s why the news coming out of Revolution Medicines this week is genuinely striking. Their experimental drug, daraxonrasib, nearly doubled survival time in patients with advanced pancreatic cancer in a large Phase 3 clinical trial — and reduced the risk of death by 60%. Those are not incremental numbers. For a disease that has resisted almost every treatment thrown at it for decades, this is a meaningful shift.

“This gene has been really undruggable up until now. It’s like pushing on an accelerator driving all the growth and division of cancer cells.”— Dr. Deedra Cohen, Co-Director, Center of Excellence for Pancreatic Cancer, Mount Sinai Tish Cancer Center

The drug targets something called the KRAS mutation — a genetic glitch found in over 90% of pancreatic cancer cases. For years, researchers knew KRAS was the engine driving tumor growth, but they couldn’t find a way to shut it off. The mutation kept slipping past every drug they tried. Daraxonrasib, a KRAS inhibitor taken orally, appears to have finally found the switch.

WHY KRAS MATTERS — AND WHY IT TOOK SO LONG

KRAS is a gene that, when mutated, acts like a stuck accelerator — constantly telling cancer cells to grow and divide. Researchers have known about it since the 1980s, but the protein it produces has a smooth surface with almost no chemical “handles” for drugs to grip. That changed recently with advances in molecular design. KRAS mutations are also found in up to 30% of all cancers, including common colon and lung cancers — meaning a working KRAS drug could eventually reshape treatment far beyond pancreatic cancer alone.

The FDA has granted expanded access to daraxonrasib, meaning patients don’t have to wait for full approval to potentially access it. Full approval is expected either late this year or in early 2027 — an unusually short horizon for a drug that was considered science fiction just a few years ago.

There’s also a second development worth paying attention to: a personalized pancreatic cancer vaccine that showed durable survival results in patients with localized disease. It’s earlier in development — currently in Phase 2 trials testing efficacy — but the concept of training your own immune system to recognize and attack your specific tumor is exactly the kind of precision medicine that researchers have been chasing since the first human genome was mapped in the early 2000s. The promise back then was that medicine would one day be able to pinpoint and target cancer with surgical accuracy. We may finally be getting there.

Now: FDA expanded access program open — eligible patients can apply through their oncologist

Late 2026 / Early 2027: Full FDA approval of daraxonrasib expected

Ongoing: Personalized pancreatic cancer vaccine in Phase 2 efficacy trials

Future: KRAS inhibitor research expanding to colon and lung cancer applications

For the roughly 66,000 Americans diagnosed with pancreatic cancer each year, and the families sitting across the table from an oncologist right now, this news matters in a very real way. It doesn’t cure anything yet. But a disease that once offered little more than palliative care now has a drug that meaningfully extends life — and a pipeline of treatments that suggests the progress isn’t stopping here.

It took longer than it should have. The biology was hard, the funding was inconsistent, and for too long, pancreatic cancer didn’t get the same research urgency as more common cancers. But the science caught up. And for patients who previously had almost no good options, catching up is everything.

Photo by National Cancer Institute on Unsplash